GSK plc announced on December 12, 2025, that the European Medicines Agency's CHMP provided a positive opinion for Nucala (mepolizumab) as a treatment for chronic obstructive pulmonary disease (COPD), based on significant trial results showing a 21% reduction in exacerbations compared to placebo.